Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) is a great challenge
in the treatment of thyroid cancer. Tyrosine kinase inhibitors (TKIs), like sorafenib and
lenvatinib which have been approved by food and drug administration (FDA), could not be
affordable for most of the Chinese patients. Apatinib is a highly selective VEGFR2 inhibitor
and reduces the angiogenesis of tumor effectively, which is a proven and effective drug in
many solid tumors. A phase II study aims to assess the efficacy and safety of apatinib in
RAIR-DTC ,which enrolled 20 patients and 10 of them had obtained a shout-term efficacy,
demonstrating the peculiar potential in treatment of RAIR-DTC. In this study, the
investigators aim to further explore the efficacy and safety of apatinib in RAIR-DTC.